Currently ongoing grants Health, EIC
Horizon Work Programme 2021-2027
GUIDE.MRD
Project 101080562101112066- HORIZON-JU-IHI-2022-01-03
GUIding multi-moDal thErapies against MRD by liquid biopsies - GUIDE.MRD
Starting Date: 1 May 2023
Grant Agreement: 101112066
Project Cost: € 34.452.565
EC Funding: € 17.660.955
IMMUTOL
Project 101080562- HORIZON-HLTH-2022-DISEASE-06-two-stage
Advanced Antigen-Specific Dendritic Cell-Based Therapy to Re-establish Tolerance in Immune-Mediated Diseases
Starting Date: 1 May 2023
Grant Agreement: 101080562
Project Cost: € 5.999.340
PROTO
Project 101095635- HORIZON-HLTH-2022-STAYHLTH-02-01
Advanced PeRsOnalized Therapies for Osteoarthritis –Tackling inflammation to improve patient outcomes
Starting Date: 1 January 2023
Grant Agreement: 101095635
Project Cost: € 7.447.875
T-FITNESS
Project 101070740 - HORIZON-EIC-2021-PATHFINDERCHALLENGES-01
Fine-Tuning T Cell Networks of Exhaustion by Synthetic Sensors
Starting Date: 1 September 2022
Grant Agreement: 101070740
Project Cost: € 3.789.472
geneTIGA
Project 101057438 - HORIZON-HLTH-2021-TOOL-06
Gene-edited T cells combating IgA Nephropathy
Starting Date: 1 July 2022
Grant Agreement: 101057438
Project Cost: € 5.736.859
TwistedNano
Project 101046424 - HORIZON-EIC-2021-PATHFINDEROPEN-01
Twisted nanophotonic technology for integrated chiroptical sensing of drugs on a chip
Starting Date: 1 April 2022
Grant Agreement: 101046424
Project Cost: € 3.197.925
Currently ongoing grants RIA, CSA, IMI
H2020 Work Programme 2018-2020
RESTORE
CSA - Large Scale Research Initiative
RESTORE Health by Advanced Therapies (Advanced Therapy Medicinal Products and Biologized Medical Devices) – ALL for Advanced Therapies – with Passion – For Patients’
Starting Date: 1 March 2019
Grant Agreement: 820292
Project Cost: € 1.000.000
EU Contribution: € 1.000.000
ReSHAPE
RIA BHC 09-2018
Reshaping undesired Inflammation in challenged Tissue Homeostasis by Next-Generation regulatory T cell (Treg) Approaches - from Advanced Technology Developments to First-in-Human Trials
Starting Date: 1 January 2019
Grant Agreement: 825392
Budget: € 13.137.396,25
NECESSITY
IMI Grant
New Clinical Endpoints in primary Sjögren’s Syndrome: an Interventional Trial based on stratifying patients
Starting Date: 1 January 2019
Grant Agreement: 806975
Project Cost: € 15.485.964,84
EU Contribution: € 8.200.000,00
LIVERSCREEN
RIA BHC 30-2019
Screening for liver fibrosis - population-based study across European countries
Starting Date: 1 January 2020
Grant Agreement: 847989
HDM-FUN
RIA BHC14-2019
Host directed medicine in invasive fungal infection
Starting Date: 1 January 2020
Grant Agreement: 847507
HIPGEN
RIA - Research and Innovation action
Placenta-expanded adherent stromal cells (plx-pad) as an innovative therapy for improving recovery and survival following hip fracture arthroplasty - HIPGEN, a multicenter phase III trial
Starting Date: 1 January 2018
Grant Agreement: 779293
PACE
RIA - Research and Innovation action
A multicenter phase III study using HLA-unmatched allogeneic placenta-derived stromal cells (PLX-PAD) for the treatment of severe critical limb ischemia accompanied by mechanistic studies
Starting Date: 1 January 2017
Grant Agreement: 733006
LIVERHOPE
RIA - Research and Innovation action
Simvastatin and Rifaximin as new therapy for patients with decompensated cirrhosis
Starting Date: 1 January 2017
Grant Agreement: 731875
Currently ongoing grants MSCA - ITN - DN
H2020 Work Programme 2018-2020 | Horizon Work Programme 2021-2027
TOLERATE
MSCA-DN
An integrated approach to restore tolerance in autoimmune disease
Starting Date: 1 October 2022
Grant Agreement: 101072729
Budget: € 2.109.650,40
INsTRuCT
MSCA-ITN (ETN)
INnovative Training in Myeloid Regulatory Cell Therapy
Starting Date: 1 January 2020
Grant Agreement: 860003
Budget: € 4.021.026,84
EDUC8
MSCA-ITN (ETN)
Early Stage Researchers EDUCational Program on Factor VIII Immunogenicity
Starting Date: 1 April 2020
Grant Agreement: 859974
INTEGRATA
MSCA-ITN (ETN)
Integrating chemical and biological approaches to target NAD production and signaling in cancer
Starting Date: 1 November 2018
Grant Agreement: 813284
Budget: € 3.738.573,00
Innovation Acta
H2020 Success rate